CN102947706B - 预测药物敏感性、抗性和疾病进展的组合物和方法 - Google Patents

预测药物敏感性、抗性和疾病进展的组合物和方法 Download PDF

Info

Publication number
CN102947706B
CN102947706B CN201180030332.9A CN201180030332A CN102947706B CN 102947706 B CN102947706 B CN 102947706B CN 201180030332 A CN201180030332 A CN 201180030332A CN 102947706 B CN102947706 B CN 102947706B
Authority
CN
China
Prior art keywords
molecule
cells
cancer
sample
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180030332.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102947706A (zh
Inventor
D·P·克拉克
A·沙姚伟茨
C·卡布拉迪拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarker Strategies LLC
Original Assignee
Biomarker Strategies LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarker Strategies LLC filed Critical Biomarker Strategies LLC
Priority to CN201810296066.8A priority Critical patent/CN108535465A/zh
Publication of CN102947706A publication Critical patent/CN102947706A/zh
Application granted granted Critical
Publication of CN102947706B publication Critical patent/CN102947706B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201180030332.9A 2010-04-19 2011-04-18 预测药物敏感性、抗性和疾病进展的组合物和方法 Expired - Fee Related CN102947706B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810296066.8A CN108535465A (zh) 2010-04-19 2011-04-18 预测药物敏感性、抗性和疾病进展的组合物和方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US32571710P 2010-04-19 2010-04-19
US61/325,717 2010-04-19
US35649510P 2010-06-18 2010-06-18
US61/356,495 2010-06-18
US42117810P 2010-12-08 2010-12-08
US61/421,178 2010-12-08
US201161443146P 2011-02-15 2011-02-15
US61/443,146 2011-02-15
PCT/US2011/032935 WO2011133477A2 (en) 2010-04-19 2011-04-18 Compositions and methods for prediction of drug sensitivity, resistance, and disease progression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810296066.8A Division CN108535465A (zh) 2010-04-19 2011-04-18 预测药物敏感性、抗性和疾病进展的组合物和方法

Publications (2)

Publication Number Publication Date
CN102947706A CN102947706A (zh) 2013-02-27
CN102947706B true CN102947706B (zh) 2018-04-13

Family

ID=44834747

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180030332.9A Expired - Fee Related CN102947706B (zh) 2010-04-19 2011-04-18 预测药物敏感性、抗性和疾病进展的组合物和方法
CN201810296066.8A Pending CN108535465A (zh) 2010-04-19 2011-04-18 预测药物敏感性、抗性和疾病进展的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810296066.8A Pending CN108535465A (zh) 2010-04-19 2011-04-18 预测药物敏感性、抗性和疾病进展的组合物和方法

Country Status (12)

Country Link
US (1) US9766249B2 (enExample)
EP (1) EP2561368B1 (enExample)
JP (2) JP6158078B2 (enExample)
KR (1) KR101977875B1 (enExample)
CN (2) CN102947706B (enExample)
AU (1) AU2011242990B2 (enExample)
CA (1) CA2795362C (enExample)
ES (1) ES2650674T3 (enExample)
HK (1) HK1258688A1 (enExample)
PL (1) PL2561368T4 (enExample)
SG (1) SG184507A1 (enExample)
WO (1) WO2011133477A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110160080A1 (en) 2008-05-14 2011-06-30 Chang Sherman H Diagnosis of Melanoma and Solar Lentigo by Nucleic Acid Analysis
CA2767616A1 (en) 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
WO2014145705A2 (en) 2013-03-15 2014-09-18 Battelle Memorial Institute Progression analytics system
CN104152397A (zh) * 2013-05-13 2014-11-19 复旦大学 一种致敏动物的脾细胞模型及其在药物筛选中的用途
GB201314485D0 (en) * 2013-08-13 2013-09-25 Electrophoretics Ltd Materials and methods relating to pancreatic cancer
JP2016540993A (ja) * 2013-09-30 2016-12-28 第一三共株式会社 タンパク質生体マーカー及びその使用
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
CN104745700A (zh) * 2015-03-27 2015-07-01 南京医科大学 一种食管癌相关甲基化生物标志物及应用
HUE044139T2 (hu) * 2015-07-07 2019-09-30 Hoffmann La Roche Kombinált terápia egy HER2-ellenes antitest-gyógyszer konjugátummal és bcl-2 inhibitorral
EP4779643A2 (en) 2016-02-02 2026-07-22 Guardant Health, Inc. Cancer evolution detection and diagnostic
CN105524973A (zh) * 2016-03-15 2016-04-27 南京华奥生物医药技术有限公司 利用自体肿瘤与正常配对原代细胞筛选肿瘤药物的方法
CN107091930B (zh) * 2017-03-07 2020-09-15 杭州百凌生物科技有限公司 快速预测和提高非小细胞肺癌细胞对表皮细胞生长因子受体抑制剂敏感性的方法
CN107271672B (zh) * 2017-06-21 2019-01-01 首都医科大学附属北京友谊医院 外泌体p-ERK在制备结直肠癌诊断产品中的应用
KR102094802B1 (ko) * 2017-10-24 2020-03-31 고려대학교 산학협력단 소변 대사체 분석을 이용한 베체트병의 진단방법
AU2018368639B2 (en) * 2017-11-20 2025-02-27 Tolremo Therapeutics Ag Diagnostic method
TWI683905B (zh) * 2017-11-21 2020-02-01 長庚醫療財團法人高雄長庚紀念醫院 用於檢測川崎氏病的方法及套組以及用於治療川崎氏病的方法
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
CA3134936A1 (en) 2019-03-26 2020-10-01 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers
KR102199141B1 (ko) 2019-05-03 2021-01-06 사회복지법인 삼성생명공익재단 대장암 진단 마커 및 대장암 진단에 필요한 정보를 제공하는 방법
GB201914517D0 (en) * 2019-10-08 2019-11-20 Randox Laboratories Ltd Xbp1 isoform multiplex assay
EP4185870A1 (en) * 2020-07-24 2023-05-31 Genentech, Inc. Determining hemodilution of bone marrow aspirates using biomarkers
US20240167102A1 (en) * 2021-03-02 2024-05-23 Dermtech, Inc. Predicting therapeutic response
CN115267165A (zh) * 2022-08-15 2022-11-01 海仕兰(上海)生物科技有限公司 一种悬浮芯片系统及其应用以及基于悬浮芯片系统对肿瘤伴随诊断因子检测方法
KR102991942B1 (ko) * 2022-09-14 2026-07-15 아주대학교산학협력단 항암제 내성 측정용 바이오 마커 및 이를 이용한 항암제 내성 예측 정보 제공 방법
CN118130793B (zh) * 2024-02-26 2025-07-29 赣南医科大学 视网膜母细胞瘤的生物标志物cdk12及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218122B1 (en) * 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
WO2006026710A2 (en) * 2004-08-31 2006-03-09 The Johns Hopkins University Rapid prognostic assay for malignancies treated with epidermal growth factor receptor
MX2007013985A (es) * 2005-05-09 2008-02-22 Theranos Inc Sistemas de fluidos de punto de cuidado y usos de los mismos.
AU2006247067B2 (en) * 2005-05-18 2012-06-07 Novartis Ag Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling
EP1904657B1 (en) * 2005-06-08 2011-05-25 Hitachi Chemical Research Center, Inc. METHOD FOR PREDICTING IMMUNE RESPONSE TO NEOPLASTIC DISEASE BASED ON mRNA EXPRESSION PROFILE IN NEOPLASTIC CELLS AND STIMULATED LEUKOCYTES
ES2380651T3 (es) * 2005-09-01 2012-05-17 Bristol-Myers Squibb Company Biomarcadores y procedimientos para determinar la sensibilidad a moduladores de recpetor 2 del factor de crecimiento endotelial vascular
WO2007143183A2 (en) * 2006-06-04 2007-12-13 Soner Altiok Methods for developing and assessing therapeutic agents
MX2009008981A (es) * 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
EP2860247A1 (en) * 2007-08-21 2015-04-15 Nodality, Inc. Methods for diagnosis, prognosis and methods of treatment
US9121801B2 (en) * 2007-10-24 2015-09-01 Biomarker Strategies, Llc Methods and devices for cellular analysis
US20110158944A1 (en) * 2007-11-30 2011-06-30 Hosted Thomas J Braf biomarkers

Also Published As

Publication number Publication date
PL2561368T3 (pl) 2018-03-30
WO2011133477A3 (en) 2012-05-10
KR101977875B1 (ko) 2019-05-13
HK1258688A1 (zh) 2019-11-15
CA2795362A1 (en) 2012-10-02
PL2561368T4 (pl) 2018-03-30
EP2561368A2 (en) 2013-02-27
ES2650674T3 (es) 2018-01-19
JP6580546B2 (ja) 2019-09-25
JP6158078B2 (ja) 2017-07-05
AU2011242990A1 (en) 2012-11-01
US20120094853A1 (en) 2012-04-19
WO2011133477A2 (en) 2011-10-27
SG184507A1 (en) 2012-11-29
AU2011242990B2 (en) 2015-02-12
KR20130095183A (ko) 2013-08-27
CN108535465A (zh) 2018-09-14
CN102947706A (zh) 2013-02-27
JP2013525786A (ja) 2013-06-20
EP2561368B1 (en) 2017-08-02
EP2561368A4 (en) 2013-10-09
CA2795362C (en) 2018-03-20
US9766249B2 (en) 2017-09-19
JP2017106923A (ja) 2017-06-15

Similar Documents

Publication Publication Date Title
JP6580546B2 (ja) 薬物感受性、薬物抵抗性および疾患進行の予測のための組成物および方法
JP7108323B2 (ja) 細胞全体でのアッセイおよび方法
Korde et al. Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer
De Mattos-Arruda et al. Circulating tumour cells and cell-free DNA as tools for managing breast cancer
Gujral et al. Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays
CN107003300B (zh) 测量erbb信号传导通路活性以诊断和治疗癌症患者的方法
Dhandapani et al. Preclinical cancer models and biomarkers for drug development: new technologies and emerging tools
WO2009062199A1 (en) EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
JP2020514379A (ja) 治療剤選択のためのシグナル伝達経路活性の測定方法
Ertay et al. WDHD1 is essential for the survival of PTEN-inactive triple-negative breast cancer
JP2013525786A5 (enExample)
Brlek et al. TWIST1 upregulation affects E-cadherin expression in brain metastases
Dinney et al. Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum
Samson et al. Molecular and cellular characterization of two patient-derived ductal carcinoma in situ (DCIS) cell lines, ETCC-006 and ETCC-010
Meril et al. Loss of EIF4G2 mediates aggressiveness in distinct human endometrial cancer subpopulations with poor survival outcome in patients
Bleker de Oliveira et al. Analytical challenges in development of chemoresistance predictors for precision oncology
Encarnacion-Medina et al. MicroRNA expression changes in women with breast cancer stratified by DNA repair capacity levels
Lee et al. High-throughput screening for genes that prevent excess DNA replication in human cells and for molecules that inhibit them
Huang et al. Integration of antibody array technology into drug discovery and development
Metousis et al. Integration of cell-type resolved spatial proteomics and transcriptomics reveals novel mechanisms in early ovarian cancer
Shao et al. 443 Protein Typing of Circulating Microvesicles Allows Real-time Monitoring of Glioblastoma Therapy
Sakunrangsit et al. Mechanistic insight into anti-cancer activity of plumbagin in endocrine resistant and HER2-overexpressed breast cancer cells
Young A translational study in pancreatic neuroendocrine neoplasms
Ramos Characterization of Small Cell Carcinoma of the Ovary, Hypercalcemic Type
Gündel In vitro modeling of tumor-stroma-crosstalk in pancreatic cancer leads to new insights into drug resistance and discovery

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180413